| 1.76 0.01 (0.57%) | 07-03 12:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.45  |
1-year : | 2.83 |
| Resists | First : | 2.1 |
Second : | 2.42 |
| Pivot price | 1.82 |
|||
| Supports | First : | 1.58 | Second : | 1.31 |
| MAs | MA(5) : | 1.78 |
MA(20) : | 1.86 |
| MA(100) : | 3.06 |
MA(250) : | 4.65 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 36.9 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 18 | Low : | 1.58 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AVGR ] has closed above bottom band by 36.5%. Bollinger Bands are 61.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.88 |
| Low: | 1.74 - 1.75 | 1.75 - 1.76 |
| Close: | 1.74 - 1.76 | 1.76 - 1.77 |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Thu, 27 Jun 2024
Can the Rally in Avinger (AVGR) Shares Continue? - Yahoo News UK
Wed, 19 Jun 2024
Avinger (NASDAQ:AVGR) Receives New Coverage from Analysts at StockNews.com - Defense World
Mon, 17 Jun 2024
Avinger Announces Closing of up to $24 Million Public Offering - StockTitan
Fri, 14 Jun 2024
Avinger (AVGR) Prices Up to $24M Share and Warrant Offering at $1.66/sh - StreetInsider.com
Thu, 13 Jun 2024
Avinger, Inc. (NASDAQ:AVGR) Sees Large Growth in Short Interest - Defense World
Fri, 17 May 2024
Are Medical Stocks Lagging Avinger (AVGR) This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 24.6 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 89 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | -15.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.56 |
| Profit Margin | -251.8 % |
| Operating Margin | -273.8 % |
| Return on Assets (ttm) | -58.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -1.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.96 |
| EBITDA (p.s.) | -8.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.69 |
| Price to Sales | 0.44 |
| Price to Cash Flow | -0.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|